Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > AI

<< Previous

Bullboard Posts

Next >>

Post by ChiChi2on Jul 13, 2023 6:25pm

308 Views

Post# 35540311

AI

If Antibe Therapeutics doesn't speed up the process all will be lost. Big boom is coming with AI in medicine. Generative AI is a revolutionary tool to discover new medicines and treatments. Nvidia invested $50 million into the biotech firm to use artificial intelligence (AI) for drug discovery.

Other pharma giants like Bayer (BAYRY), Roche (RHHBY), Sanofi (SNY), and AstraZeneca (AZN) are actively using AI technology for drug discovery purposes.

<< Previous

Bullboard Posts

Next >>

From now on, dynaCERT instead of Bitcoin or NVIDIA?